$2.1M
1 filing since 2023 · latest SAFE filed
Contamination Source Identification, Inc. (CSI-Dx) is a Pennsylvania molecular diagnostics company that develops an RNA-sequencing test for identifying active infections. The CSI-Dx test directly isolates and identifies bacterial, viral, and other pathogenic microorganisms present in a clinical sample by detecting pathogenic RNA. Current validation work focuses on identifying prosthetic joint infections and determining the causative agents of sepsis. The company is led by CEO Gary Shope alongside R&D and bioinformatics leadership drawn from microbial genomics research.
What sets it apart
An untargeted sequencing assay that identifies whatever pathogens are actively present in a sample rather than testing for a preselected panel of organisms, so co-infections that targeted tests miss can still be detected.
A genomic sequencing diagnostic test that isolates and identifies active bacterial, viral, and other pathogenic microorganisms in a clinical sample by detecting pathogenic RNA.
